How Absci, Generate:Biomedicines, Xaira, Nabla Bio, BigHat Biosciences, Cradle, EvolutionaryScale, Chai Discovery, LabGenius, Adaptyv.
AI-native antibody discovery, ADC (antibody-drug conjugate), bispecific, multispecific, biologics design is the hottest oncology, immunology, rare-disease modality in 2026 — validated by the $100B+ ADC M&A supercycle (Pfizer-Seagen $43B Dec-2023, AbbVie-ImmunoGen $10.1B Feb-2024, BMS-SystImmune $8.4B Dec-2023 upfront-plus-milestones, Merck-Daiichi Sankyo $22B partnership Oct-2023 for patritumab deruxtecan, ifinatamab deruxtecan, raludotatug deruxtecan, J&J-Ambrx $2B Jan-2024, Genmab-ProfoundBio $1.8B Apr-2024, AbbVie-Landos $137M+milestones May-2024). AI-native platforms — Absci $NASDAQ:ABSI (integrated wet-lab, generative-AI antibody de-novo design, ACE Assay, Bionic Protein Discovery, Merck, AstraZeneca, Almirall partnerships), Generate:Biomedicines ($273M C Sep-2023, $273M D Q4-2024 Flagship-NVentures-Amgen, generative-biology, Chroma, protein-generation, Novartis-Amgen partnerships → $2.3B valuation), Xaira Therapeutics ($1B seed Apr-2024 ARCH-Foresite-Sequoia-NEA-Lightspeed-Lux-Menlo-Two Sigma-SV Angel-8VC, ex-Genentech David Baker RFdiffusion, Institute for Protein Design UW), Nabla Bio ($26M A Feb-2024 Radical, JoinLab-adj-Khosla, generative-antibody-design, AbCellera partnership), BigHat Biosciences ($75M B Q2-2024 Section 32-Andreessen Horowitz a16z-Amgen, ML-guided-antibody-engineering, Milliner platform, Merck partnership), Cradle ($73M B Q2-2024 IVP-Index-Kindred-Kevin Systrom, protein-design-copilot, Novozymes-Grifols-Twist-Johnson & Johnson partnerships), EvolutionaryScale ($142M seed Q3-2024 Nat Friedman-Daniel Gross-Lux, ESM3 open-source, ex-Meta FAIR team), Chai Discovery ($30M seed Q4-2024 OpenAI-Thrive-Dimension, Chai-1 open-source, Amgen partnership), LabGenius ($28M B Q2-2023 M Ventures-Kindred-Atomico, EVA robotic-lab, Sanofi partnership), Adaptyv Biosystems (protein-testing-as-a-service, $6.5M seed 2024, Fifty Years-Y Combinator) — finally proved LLM, diffusion, geometric-deep-learning, evolutionary-scale-modeling for antibody, ADC, bispecific, multispecific, biologics de-novo design at commercial-partnership scale.
Four unlocks: (1) $100B+ ADC, bispecific, T-cell-engager M&A supercycle (Pfizer-Seagen $43B, AbbVie-ImmunoGen $10.1B, BMS-SystImmune $8.4B, Merck-Daiichi $22B, J&J-Ambrx $2B, Genmab-ProfoundBio $1.8B) validated next-gen-modality as the dominant pharma-BD priority. (2) AlphaFold 3, RFdiffusion, ESM3, Chai-1, Boltz-2, ProteinMPNN, LigandMPNN, IgFold, AbLang, BALM, PALM-H3, FrameDiff, Chroma, Genie, DiffAb finally reached commercial de-novo antibody, ADC, bispecific design at big-pharma-partnership scale — validated by Merck, AstraZeneca, Novartis, Amgen, Sanofi, J&J, Novozymes, Grifols, Twist, AbCellera partnerships across Absci, Generate, BigHat, Cradle, Chai, Nabla, LabGenius. (3) Xaira $1B seed Apr-2024 ARCH-Foresite-Sequoia-NEA-Lightspeed-Lux-Menlo-Two Sigma-SV Angel-8VC reset the biotech-seed-round bar and validated ex-Genentech David Baker RFdiffusion, Institute for Protein Design UW as the reference-team. (4) FDA AI/ML Action Plan, FDA AI/ML SaMD, FDA Digital Health Center of Excellence, PDUFA VII, BsUFA IV, Fast Track, Breakthrough Therapy, Accelerated Approval, RMAT, Orphan Drug, Rare Pediatric Disease Voucher regulatory-clarity finally reached AI-assisted-discovery, AI-augmented-CMC, AI-augmented-clinical-trial-design maturity.
Seed $5-100M+ for platform, first-hit, first-lead-candidate, first-partnership (LabGenius $28M B M Ventures-Kindred-Atomico, Nabla $26M A Radical, Chai $30M seed OpenAI-Thrive-Dimension, EvolutionaryScale $142M seed Nat Friedman-Daniel Gross-Lux, Xaira $1B seed ARCH-Foresite-Sequoia-NEA-Lightspeed-Lux-Menlo-Two Sigma-SV Angel-8VC outlier). Series A/B $30-300M for first-IND, first-clinical-candidate, first-multi-target-partnership, first-CMC, first-cGMP (BigHat $75M B Section 32-a16z-Amgen, Cradle $73M B IVP-Index-Kindred-Kevin Systrom, Generate $273M C+D Flagship-NVentures-Amgen). Series C/D, crossover, IPO $200M-$1B+ for Phase 1/2/3, BLA, first-approval, multi-billion big-pharma-partnership, IPO (Absci $NASDAQ:ABSI IPO Jul-2021, Generate $2.3B, Recursion-Exscientia $850M all-stock merger Aug-2024). Non-dilutive material — NIH R01/R21/R43/R44 SBIR-STTR, BARDA, DARPA, ARPA-H, CIRM, Wellcome Leap, Gates Foundation, Chan Zuckerberg, Novo Nordisk Foundation, Wellcome Trust, Cancer Research UK, LEO Foundation, Milken, Longevity Impetus Grants, Astera Institute, Convergent Research, Focused Research Organizations FRO, Renaissance Philanthropy, Schmidt Sciences, Simons Foundation, HHMI Howard Hughes Medical Institute, Wu Tsai Neurosciences, Wu Tsai Human Performance Alliance, Wu Tsai Innovative Lung Cancer Research, Broad Institute, Whitehead Institute, Salk Institute, Cold Spring Harbor, Scripps, UCSF, Stanford, Harvard, MIT, Yale, Caltech, Princeton, Columbia, Cornell, Chicago, Michigan, UW, UCLA, UCSD, Berkeley, JHU Johns Hopkins, Duke, Penn, Rockefeller, Sloan Kettering MSKCC, MD Anderson, Dana-Farber, Mayo, Cleveland Clinic, Kaiser Permanente, NCI Cancer Moonshot, NHS, NIHR, Cancer Research UK, LEO Foundation, Novo Nordisk Foundation, Wellcome Trust, European Research Council ERC, Horizon Europe, Innovative Health Initiative IHI, IMI Innovative Medicines Initiative-EFPIA, BMBF, DFG, INSERM, CNRS, ANR, AIRC, Telethon, FWO, FWF, SNSF, JST, AMED, KIST, KAIST, POSTECH, Seoul National University, Peking University, Tsinghua, Fudan, Shanghai Jiao Tong, Zhejiang, IIT, IISc, TIFR, Weizmann, Technion non-dilutive grant, partnership, strategic-alliance.
Overclaiming platform-validation without big-pharma-partnership, IND-track, third-party-benchmark, hit-rate, developability, affinity, specificity, immunogenicity, PK, PD, manufacturability, CMC benchmark — post-Absci Merck-AstraZeneca-Almirall, Generate Novartis-Amgen $370M upfront, BigHat Merck, Cradle Novozymes-Grifols-Twist-J&J, Chai Amgen credible-partnership bar, operators without a signed, published, third-party-validated big-pharma-partnership, IND-track get flagged by Flagship, ARCH, Foresite, Sequoia, NEA, Lightspeed, Lux, Menlo, Two Sigma, 8VC, a16z Bio+Health, Section 32, Radical, Amgen Ventures, Merck M Ventures, Pfizer, Novartis, Sanofi, AbbVie, AstraZeneca, J&J, Roche, Lilly, Bayer, Boehringer, GSK, Takeda, Novo Holdings diligence within 12-18 months. Underestimating linker-payload, conjugation-chemistry, CMC, cGMP, tech-transfer, Lonza, Catalent, Samsung Biologics, WuXi Biologics, WuXi AppTec, Sartorius, Cytiva-Danaher, Corning, Thermo Fisher, Merck-Millipore-Sigma, Fujifilm Diosynth, AGC Biologics, AbbVie Contract Manufacturing, BioCentriq, BiOptus, Aldevron-Danaher, Charles River, Piramal Pharma, Recipharm, Patheon-Thermo, Cambrex, Almac, Emergent BioSolutions, KBI Biopharma-JSR, Rentschler, Boehringer BIP, Kymab-Sanofi contract, partnership, tech-transfer. Ignoring FDA, EMA, PMDA, NMPA, Health Canada, TGA, MHRA, Swissmedic, ANVISA, COFEPRIS, FDA AI/ML Action Plan, FDA AI/ML SaMD, FDA Digital Health Center, PDUFA VII, BsUFA IV, Fast Track, Breakthrough, Accelerated Approval, RMAT, Orphan, Rare Pediatric Voucher regulatory-clarity, posture.
Investor directory · Fundraising library · Articles A–Z · Company funding database